[CAS NO. 688347-51-5] SPL-334
PRODUCTS SPECIFICATIONS [688347-51-5]
DESCRIPTION [688347-51-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 433.50 |
| Molecular Formula | C22H15N3O3S2 |
| SMILES | N#CC1=C(CSC2=NC3=C(C(N2CC4=CC=C(C(O)=O)C=C4)=O)SC=C3)C=CC=C1 |
Summary
SPL-334 is a potent and selective S-Nitrosoglutathione reductase (GSNOR) inhibitor. SPL-334 causes a significant reduction in the production of Th2 cytokines IL-5 and IL-13 and the levels of the chemokine CCL11 (eotaxin-1) in the airways. SPL-334 can be used in research of allergic airway inflammation [1] .
In Vivo
SPL-334 (0.1-1 mg/kg; Intranasal administration; daily, for 7 d; BALB/c recipient mice with DO11.10 CD4+ Th2 xenograft) causes a reduction in allergic airway inflammation [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | BALB/c recipient mice with DO11.10 CD4+ Th2 xenograft [1] |
| Dosage: | 0.1 or 1 mg/kg |
| Administration: | Intranasal administration; daily, for 7 days |
| Result: |
Caused a significant reduction in the influx of lymphocytes and eosinophils into the airways and the level of EPO in the BALF.
Reduced the number of OVA-specific T cells and eosinophils during allergic airway inflammation. Reduced in peribronchial inflammation and mucus secretion during airway inflammation. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.